Format

Send to

Choose Destination
Best Pract Res Clin Haematol. 2015 Jun-Sep;28(2-3):124-32. doi: 10.1016/j.beha.2015.10.009. Epub 2015 Oct 22.

Is there a role for therapy after transplant?

Author information

1
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX, USA. Electronic address: boran@mdanderson.org.

Abstract

Despite the steady increase in the number of stem cell transplants performed since 1980 and improvements in survival rates, disease relapse remains the major cause of death after HLA matched sibling and unrelated donor transplants for acute myeloid leukemia (AML). Given this situation, maintenance therapy after transplant may be an appropriate strategy to reduce the relapse rate and prolong survival. A number of agents are being investigated as maintenance therapy after stem cell transplant in AML patients, including azacitidine, decitabine, and other agents. This paper focuses on the role of maintenance treatment to reduce the risk of relapse after transplant.

KEYWORDS:

Acute myeloid leukemia; Azacitidine; Decitabine; Hematopoietic stem cell transplant; Maintenance therapy; Panobinostat; Quizartinib; Sorafenib

PMID:
26590769
DOI:
10.1016/j.beha.2015.10.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center